XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Equity Incentive Plans and Stock-Based Compensation - Restricted Stock Units and Performance-Based Restricted Stock Units - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized compensation cost $ 24.2  
Unrecognized compensation expense, weighted average period 2 years 3 months 18 days  
Outstanding and unvested (in shares) 1,160,986 507,925
Weighted-average grant date fair value, outstanding and unvested (USD per share) $ 27.31 $ 17.43
Restricted stock units | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period 2 years  
Restricted stock units | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period 3 years  
Performance-based restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period 2 years  
Unrecognized compensation cost $ 6.0  
Unrecognized compensation expense, weighted average period 11 months 26 days  
Target level of achievement percentage 100.00%  
Performance-based restricted stock units | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting rights, percentage 0.00%  
Performance-based restricted stock units | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting rights, percentage 200.00%  
Performance-Based Restricted Stock Units, TSR Goal    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding and unvested (in shares) 354,532  
Weighted-average grant date fair value, outstanding and unvested (USD per share) $ 29.15  
Performance-Based Restricted Stock Units, Clinical Development Milestones    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding and unvested (in shares) 354,532  
Weighted-average grant date fair value, outstanding and unvested (USD per share) $ 17.57